Clinical Trial Detail

NCT ID NCT04146038
Title Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rutgers, The State University of New Jersey
Indications

myelodysplastic syndrome

chronic myelomonocytic leukemia

acute myeloid leukemia

myeloproliferative neoplasm

Therapies

Decitabine + Salsalate + Venetoclax

Azacitidine + Salsalate + Venetoclax

Age Groups: adult senior

No variant requirements are available.